1. Introduction {#sec1}
===============

Receptor tyrosine kinases (RTKs) are a large family of kinase enzymes targeted by different chemotherapeutic medications. The main role of RTKs is to phosphorylate the tyrosine amino acid in several proteins aided by ATP (γ-phosphoryl group donor).^[@ref1],[@ref2]^ This phosphorylation activates the signaling pathway at the cellular level, which is a crucial process for differentiation, proliferation, migration, and antiapoptotic pathway. However, dysregulation of RTK signaling at the cellular level leads to an assortment of human diseases, most notably cancers.^[@ref3],[@ref4]^ The vascular endothelial growth factor 2 (VEGFR2) and c-mesenchymal epithelial transition factor (c-Met) are RTKs which are linked to the hepatocyte growth factor and endothelial cells, respectively. These RTKs activate the phosphorylation cascade of different tyrosines through the dimerization process aided by ATP to terminally induce cell growth.^[@ref5]−[@ref7]^ The role of c-Met and VEGFR2 is complementary in the process of induction of angiogenesis of human cancer cells.^[@ref8],[@ref9]^ This significant role in tumorigenesis has received great attention in different research groups^[@ref10]−[@ref13]^ for dual targeting VEGFR2 and c-Met kinases by novel antiangiogenic agents, as represented in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}.

![Isatin derivatives having a notable inhibitory activity against VEGFR2 kinase.](ao0c02038_0001){#fig1}

On the other hand, the isatin moiety was intensively reported as a key scaffold in several chemotherapeutic agents acting as VEGFR2 and/or c-Met inhibitors. Sunitinib (**I**; *K*~i~ = 9.0 nM), an isatin derivative targeting multiple tyrosine kinase, was clinically approved in 2006 as an angiogenic anticancer agent for the therapy of renal cell carcinoma.^[@ref14]^ Orantinib (**II**, SU6668) is another isatin analogue in phase I for the treatment of solid tumors exhibiting a significant effect on multiple tumors in xenograft models. It reveals its effect through inhibition of multiple kinases including VEGFR2 (*K*~i~ = 9.0 nM).^[@ref15]^ Likewise, SU14813 (**III**) is an orally active oxindole derivative, which inhibits multiple kinases including VEGFR2 (IC~50~ = 0.04 μM).^[@ref16]^ The preclinical trials proposed its use in combination with docetaxel to significantly affect different tumor xenograft models.^[@ref17]^ Other isatin derivatives such as compounds (**IV**) and (**V**) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) were designed to target VEGFR2 kinase (IC~50~ = 0.31 and 0.18 μM, respectively).^[@ref18],[@ref19]^ These analogues are indolinone-ureid hybrids that were designed to fit within the active site of the VEGFR2 enzyme targeting its key amino acids.

The c-Met kinase is the second target of interest to share VEGFR2 in the angiogenesis process within the cancer cells. Similar to VEGFR2, many isatin derivatives targeted c-Met kinase as inhibitors, for instance, an oxindole derivative (SU11274, **VI**[Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) that downregulates the viability of NSCLC cells via the inhibition of c-Met kinase with IC~50~ = 12 nM.^[@ref20],[@ref21]^ 3-Hydrazinoindolin-2-one derivatives (**VIIa,b**, and **VIII**; [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) are equipotent inhibitors for c-Met kinase as well, with IC~50~ = 7 nM.^[@ref22]^ Compound **VIII** was cocrystallized with c-Met kinase and submitted to the protein data bank (PDB code: 3ZZE).^[@ref23]^

![Potent c-Met kinase inhibitors containing an isatin nucleus.](ao0c02038_0002){#fig2}

Many of the above-mentioned scaffolds with a triazole ring fused to aryl-substituted six-membered heterocycles and/or isatin functionalities were intensively reported to have potent c-Met kinase inhibitory activities.^[@ref24]−[@ref32]^ Moreover, different nitrogenous fused and hybrid heterocyclic compounds (pyrrolotriazine, benzimidazole, imidazopyridine, thienopyrimidine, and dioxoquinazoline) were reported to be promising dual-acting VEGFR2 and c-Met inhibitors.^[@ref33]−[@ref38]^ Besides, the compounds containing triazolothiadiazine fragments were reported to possess a broad spectrum of activities such as antitumor, antibacterial, antiviral, antifungal, and PDE4 inhibitory activities.^[@ref39]−[@ref42]^

1.1. Rational Design {#sec1.1}
--------------------

The rational design of our hybrid isatin and triazolothiadiazine compounds depends mainly on the aforementioned significant dual inhibitory activities of isatin and oxindole against VEGFR2 and c-Met-mediated tumorigenesis ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).

![Rational design of hybrid isatin and triazolothiadiazine compounds.](ao0c02038_0003){#fig3}

Such numerous reported studies for targeting VEGFR2 and c-Met-mediated tumorigenesis have drawn tremendous interest and prompt us to synthesize a series of hybrid 3-hydrazino-indolin-2-one derivatives (**6a--y**; [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). The synthesized compounds include two series of 3-hydrazino-indolin-2-one derivatives in which the terminal N is directly attached to the \[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine moiety. These compounds were investigated for their cytotoxic activity by the National Cancer Institute (NCI, USA) at 10 μM in a full NCI 58 cell panel. Then, the most active compound was screened for its inhibitory activities against VEGFR2 and c-Met kinases, and a molecular docking study was conducted to justify its mode of kinase inhibition. Additionally, the promising compounds were subjected to an in vivo hen's egg-chorioallantoic membrane (HET-CAM) study to check their angiogenic effects.

![Synthesis of Compounds **5a--d** and the Target Compounds **6a--y**\
Reaction conditions: (a) Bromoalkanes, anhydrous DMF, K~2~CO~3~, rt, 24 h or reflux, 3 h, (b) 1 N HCl, reflux, 50 min, (c) EtOH, reflux, 1 h.](ao0c02038_0008){#sch1}

2. Results and Discussion {#sec2}
=========================

2.1. Chemistry {#sec2.1}
--------------

The synthesis of target compounds **6a--y** was carried out, as shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. The requisite N-substituted isatin **2** was prepared by alkylation from their N-unsubstituted analogues as reported^[@ref43]−[@ref45]^ with bromoalkanes under anhydrous condition via stirring in dimethylformamide (DMF) or acetonitrile in the presence of K~2~CO~3~ in room temperature overnight or under reflux. The synthesis of the requisite series of compounds 2-(6-aryl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazin-1-ium chloride (**5a--d**) was conducted by the reflux of purpald (**4**; 4-amino-5-hydrazino-1,2,4-triazole-3-thiol) and phenacyl bromides (**3**) in the presence of hydrochloric acid (1 N).^[@ref46]^ The target compounds **6a--y** were prepared by refluxing the intermediate **5** with isatin **2** in ethanol where the desired target product precipitates during the reaction, which is isolated by suction filtration, followed by recrystallization from aqueous DMF. As there is no literature precedence for the synthesis of intermediates **5a--d**, a synthetic methodology was developed for these compounds taking into account the close nucleophilicity of sulfhydryl, amino, and hydrazino groups of purpald **4**.^[@ref46]^

Many attempts were made to react 2′-bromoacetophenone (**3**; R^4^ = H) with purpald (**4**) under reflux in ethanol in the absence or presence of a base (NaOH, Na~2~CO~3~) or in the presence of acetic acid. However, these attempts resulted in a mixture of products that were difficult to purify. This reaction was successful only by reflux in 1N hydrochloric acid for 50 min, as shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}.

In a related procedure,^[@ref47]^ the benzaldehyde selectively reacted with the amino group of purpald (**4**) under reflux in aqueous ethanol in the presence of 1 N HCl to afford a very good yield. Upon application of the same method using phenacyl bromides instead of aldehydes, the desired intermediate compounds were isolated in good yields.

2.2. Biological Screening {#sec2.2}
-------------------------

### 2.2.1. In Vitro Primary Single-Dose (10 μM Concentration) Screening against NCI 58 Human Cell Panel {#sec2.2.1}

Eight representative compounds **6a**, **6b**, **6e**, **6l**, **6n**, **6r**, **6v**, and **6y** were investigated for their anticancer activities by single-dose in vitro screening at 10 μM concentration against NCI 58 human cell lines by the Developmental Therapeutics Program (DTP) in NCI (<https://dtp.cancer.gov/>).^[@ref48]^ These cell lines were collected from nine different subpanels (hematopoietic system, lung cancer, colon, brain, skin melanoma, prostate, breast, kidney, and ovary). The antiproliferative data for each compound were reported as a mean percent cell growth of the treated cancer cells in comparison to the untreated negative control cells, and the.

Percent growth inhibition (GI %) was calculated by the deduction of the percent cell growth from 100. As depicted in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, compounds **6a**, **6b**, **6e**, **6v**, and **6y** of the tested 3,5-substituted-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)indolin-2-one derivatives exhibited low to moderate nonselective inhibition of different cancer cell lines.

###### Growth Inhibition Percentage (GI %) of in Vitro Subpanel Tumor Cell Lines at Single-Dose (10 μM) Concentration for Compounds **6a**, **6b**, **6e**, **6l**, **6n**, **6r**, **6v**, and **6y**

  subpanel/cell line                      **6a**        **6b**                             **6e**   **6l**   **6n**   **6r**   **6v**   **6y**   
  --------------------------------------- ------------- ---------------------------------- -------- -------- -------- -------- -------- -------- ----
  leukemia                                CCRF-CEM      [a](#t1fn1){ref-type="table-fn"}   51                                           18       46
                                          K-562         23                                 85       14       15       19       14       33       53
                                          MOLT-4        13                                 51       17                12                18       30
                                          RPMI-8226                                        61       20                                  21       25
                                          SR            23                                 64       27       23       36       21       44       28
  NSCLS[b](#t1fn2){ref-type="table-fn"}   A549/ATCC     31                                 45       18       23       29       17       25       31
                                          EKVX          13                                                                                       12
                                          HOP-62        54                                 66                                           20       37
                                          HOP-92        36                                 22                                                    11
                                          NCI-H23       31                                 35                                           19       16
                                          NCI-H322M                                                                                              22
                                          NCI-H460      17                                 65                                           41       51
                                          NCI-H522      57                                 60       39       34       25       41       41       35
  colon cancer                            COLO 205                                         17                                                     
                                          HCC-2998      19                                 12       13                                            
                                          HCT-116       14                                 70       17                                  18       46
                                          HCT-15                                           10                                           37       43
                                          HT29          28                                 57       27       27       24       24       15       16
                                          KM12                                             40       24                                  18       22
                                          SW-620                                           21                                           16        
  CNS cancer                              SF-268        31                                 12       16                                  25       26
                                          SF-295                                           12                                           10       30
                                          SF-539        18                                 15       13                         12       18        
                                          SNB-19        17                                 37       10                                  18       26
                                          SNB-75        35                                 17       12                16       18       17        
                                          U251          50                                 37                                           15       33
  melanoma                                LOX IMVI                                         38       27                                  27       37
                                          MALME-3M                                         25                                                     
                                          M14                                              29       14                                  33       29
                                          MDA-MB-435                                       22       19                                  52       14
                                          SK-MEL-2      13                                 27       11                                  16       20
                                          SK-MEL-28                                        15                                           15       12
                                          SK-MEL-5                                         20                                           16       17
                                          UACC-257      11                                 35       20       27       20       23       19       13
                                          UACC-62                                          23                                           28       21
  ovarian cancer                          IGROV1                                           17                                           22       33
                                          OVCAR-3       12                                 17                                           22        
                                          OVCAR-4       41                                 21       26                                  22       22
                                          OVCAR-5                                          18                                                     
                                          OVCAR-8       41                                 51                                           13       20
                                          NCI/ADR-RES                                                                                            13
                                          SK-OV-3       11                                                                                        
  renal cancer                            786-0         19                                 20       12                                            
                                          A498                                             23       18                         10       24        
                                          ACHN                                             35                                           17       23
                                          CAKI-1        21                                 34       13                         11       33       25
                                          RXF 393       18                                 45       30                                  12        
                                          SN12C                                            21                                           12       25
                                          TK-10                                            29                         17                          
                                          UO-31                                                                                         27       23
  PC[c](#t1fn3){ref-type="table-fn"}      PC-3          20                                 44                         10                11       25
                                          DU-145        16                                 50       23                                           19
  breast cancer                           MCF7          29                                 28       21                         12       30       35
                                          MDA-MB-231    12                                 23       11                                           13
                                          HS 578T       28                                          14                                  27        
                                          BT-549        28                                 41       29                                  24       24
                                          T-47D         36                                 47       29                15       12       18       29
                                          MDA-MB-468                                       33                                                     
  mean growth, %                          16            31                                 10                         2        18       21       
  sensitive cell lines no.                34            52                                 30       6        11       12       14       44       

Only GI % higher than 10% are shown.

Nonsmall cell lung cancer.

Prostate cancer.

Compound **6b** revealed the most efficient antiproliferative activity (GI %), with a broad-spectrum activity against numerous cell lines that belong to diverse cancer subpanels. In particular, compound **6b** displayed a potent growth inhibitory impact against leukemia (CCRF-CEM, K-562, MOLT-4, RPMI-8226, and SR), nonsmall cell lung cancer (NCI-H522, NCI-H460, and HOP-62), colon cancer (HT29 and HCT-116), ovarian cancer (OVCAR-8), and prostate cancer (DU-145) cell lines with inhibition percents of 51, 85, 51, 61, 64, 66, 65, 60, 70, 57, 51, and 50%, respectively. In addition, compound **6b** exerted cytotoxic activity with GI equal to or greater than 35% against nonsmall cell lung cancer (A549/ATCC and NCI-H23), colon cancer (KM12), CNS cancer (SNB-19 and U251), melanoma (LOX IMVI and UACC-257), renal cancer (ACHN and RXF 393), and breast cancer (BT-549 and T-47D) cell lines with inhibition percents of 45, 35, 40, 37, 37, 38, 35, 35, 45, 41, and 47%, respectively.

Moreover, compound **6y** was found to be the second most potent analogue (mean % GI = 21) with broad-spectrum activity against different 44 cell lines. Compound **6y** showed GI equal to or greater than 35% over leukemia (CCRF-CEM and K-562), nonsmall cell lung cancer (HOP-62, NCI-H460, and NCI-H522), colon cancer (HCT-116 and HCT-15), melanoma (LOX IMVI), and breast cancer (MCF7) cell lines with inhibition percents of 46, 53, 37, 51, 35, 46, 43, 37, and 35%, respectively.

Further investigation of the obtained results in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} unveiled that leukemia (K-562 and SR), nonsmall cell lung cancer (A549/ATCC and NCI-H522), colon cancer (HT29), and melanoma (UACC-257) cell lines were susceptible to the cytotoxic effect of all tested compounds including **6a**, **6b**, **6e**, **6l**, **6n**, **6r**, **6v**, and **6y**. The susceptible cell lines to the effect of compounds **6a**, **6v**, and **6y** with GI % ≥ 35 are listed in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. The cell lines HOP-62, HOP-92, NCI-H522, SNB-75, U251, OVCAR-4, OVCAR-8, and T-47D are susceptible to compound **6a** by GI of 35--57%. However, SR, NCI-H460, NCI-H522, HCT-15, and MDA-MB-435 cells are sensitive to compound **6v** by a GI of 37--52%. Compound **6y** exhibited a GI of 35--53% against CCRF-CEM, K-562, HOP-62, NCI-H460, HCT-116, HCT-15, LOX IMVI, and MCF7 cell lines.

### 2.2.2. Angiogenesis Study {#sec2.2.2}

Twenty-one test compounds were subjected to an in vivo HET-CAM study to check their angiogenic effects. In this study, dexamethasone (DEXA) which was reported to demonstrate potent antiangiogenic activity^[@ref49]^ was used as a positive control.^[@ref50]−[@ref54]^ This study was conducted in two phases to check the mortality and toxicity of the test compounds at 40 and 100 μM concentrations against HEM-CAM. In the first phase, 40 μM of each of the test compounds dissolved in 100% dimethyl sulfoxide (DMSO) equivalent was applied onto HET-CAM on the 9th day, and the embryos were examined on the 11th day. All compounds produced 100% mortality of the chick embryos. In the second phase, 40 μL of each compound dissolved in 40% DMSO in sterile saline equivalent 40 μM was applied onto HEM-CAM on the 9th day, and then, the embryos and CAM were examined on the 11th day. Yet, at lower concentration (40 μM), eight compounds, namely, **6c**, **6e**, **6g**, **6j**, **6u**, **6v**, **6w**, and **6y**, were toxic against the HEM-CAM and the chick embryos. The other 13 compounds did not exhibit any detectable mortality against the chick embryos. [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} shows the number of newly formed blood capillaries in HET-CAM during exposure to 40 μM of the 13 nontoxic compounds in comparison to the formed ones by DEXA (0.02 μg) as a potent antiangiogenic agent and using 40% DMSO as a negative control. DEXA, the positive control, produced a 54% reduction in the number of newly formed blood capillaries (*P* \< 0.001). Seven compounds **6b**, **6d**, **6f**, **6n**, **6o**, **6t**, and **6x** showed a significant decrease in the number of blood vessels as well. Compound **6b** is the most effective derivative producing 56% reduction of angiogenesis comparable to the effect of DEXA.

![Effects of 13 newly synthesized compounds **6a**, **b**, **d**, **f**, **h**, **i**, **k--o**, **t**, and **6x** at 40 μM concentration on the number of newly formed blood capillaries of HET-CAM.](ao0c02038_0004){#fig4}

Compound **6n** was the least significantly effective (27%, *P* \< 0.05). In contrast, two compounds **6a** and **6h** produced a significant increase in the number of newly formed blood capillaries (33 and 35%, respectively), whereas the other four compounds **6i**, **6x**, **6l**, and **6m** revealed a nonstatistically significant change.

Further validation was carried out by quantitative assessment of angiogenesis on HET-CAM using image analysis. Compound **6b** (as the most effective antiangiogenic agent) and compound **6h** (which increases angiogenesis) were tested. Their effects on the angiogenesis of CAM were examined on the 11th day using computerized image analysis to count newly formed small blood vessels in the circle of 100 mm^2^ area representing a standard area for all the angiographs. [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} shows the development of new blood vessels in HEM-CAM, after the application of DMSO (vehicle), compound **6b**, and compound **6h**, respectively. The results are expressed as mean + standard error of three eggs using image analysis and compared with one-way ANOVA and Dunnett's multiple comparison test.

![Quantitative assessment of angiogenesis on HET-CAM showing the rate of development of blood vessels and capillaries after application of DMSO (vehicle), compound **6b**, and compound **6h**, respectively.](ao0c02038_0005){#fig5}

2.3. VEGFR-2, PDGFR, and C-Met Kinase Inhibitory Activities {#sec2.3}
-----------------------------------------------------------

As aforementioned, compound **6b** superiorly emerged as the most efficient antiangiogenic and antiproliferative agent; accordingly, **6b** was selected to evaluate its inhibitory activity toward VEGFR-2, PDGFR, and C-Met kinases. [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} displays the inhibition data, as IC~50~ values, for compound **6b** and the clinically used sunitinib as a standard reference. As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, **6b** exhibited good VEGFR-2, PDGFR, and C-Met submicromolar inhibitory activities with IC~50~ values equal to 435, 371, and 654 nM, respectively.

###### IC~50~ Values for the Inhibitory Activities of Compound **6b** toward VEGFR-2, PDGFR, and C-Met Kinases

              IC~50~ (nM)         
  ----------- ------------- ----- -----
  **6b**      435           371   654
  sunitinib   346           304   468

2.4. Molecular Docking Studies {#sec2.4}
------------------------------

The significant inhibitory activity of compound **6b** was deeply investigated through molecular docking simulations inside the active site of the VEGFR-2 crystal structure (PDB: 4agd).^[@ref55]^ This crystal structure contains sunitinib as a cocrystallized ligand, which was useful to obtain the key amino acids responsible for the activity. This crystal structure showed that the oxindole moiety played an important role in the biological activity by forming two hydrogen bonds with Cys919 and Glu917 (CDOCKER energy = −27.56 kcal/mol). Docking simulations showed that the oxindole moiety of compound **6b** played the same role as the H-bond with Cys919 was 2.03 Å, whereas the H-bond with Glu917 was 2.10 Å. The triazine ring and phenyl ring aided compound **6b** to be embedded in the pocket by forming a π-hydrophobic interaction and π-cation interaction with Leu840 and Lys838, respectively ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}).

![Docking mode of compound **6b** (in ball and stick view) into the binding site of VEGFR-2 (PDB: 4agd). It seems to be superimposed on the native ligand (B49; sunitinib in dark turquoise lines) within a root-mean-square deviation (rmsd) of 1.14 Å, revealing hydrogen, electrostatic, and hydrophobic binding interactions identical to sunitinib.](ao0c02038_0006){#fig6}

Compound **6b** revealed additional inhibitory activity against c-Met kinase which can be illustrated by molecular docking studies using the crystal structure of c-Met kinase downloaded from protein databank (3ZZE) cocrystallized with an inhibitor with oxindole moiety.^[@ref56]^

Compound **6b** accepts a hydrogen bond with Met1160 (2.16 Å) by an oxindole ring, which is similar to the cocrystallized ligand (CDOCKER energy = −31.23 kcal/mol). This hydrogen bond was supported by another one between the triazine ring with Tyr1159 (2.69 Å). The oxindole moiety was embedded inside the hydrophobic region consisting of Ala1108, Val 1092, Met1211, and Tyr1230 ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}).

![Docking mode of compound **6b** into the binding site of the c-Met kinase (PDB: 3zze). It was docked within an rmsd of 2.0 Å from the cocrystallized ligand (6XP; cyan lines), revealing one hydrogen bond with D1222 in addition to electrostatic and multiple hydrophobic binding interactions.](ao0c02038_0007){#fig7}

3. Conclusions {#sec3}
==============

Twenty-five 3-hydrazinoindolin-2-one derivatives directly attached to triazolo-thiadiazin-3-yl moiety (**6a--y**) were designed, synthesized, and investigated for their cytotoxicity. Eight compounds **6a**, **6b**, **6e**, **6l**, **6n**, **6r**, **6v**, and **6y** were assessed for their anticancer activity against a panel of NCI 58 tumor cell lines including nine different subpanels (hematopoietic system, lung cancer, colon, brain, skin melanoma, ovary, kidney, prostate, and breast). Five substituted 3-(triazolo-thiadiazin-3-yl)indolin-2-one derivatives revealed moderate to low broad-spectrum activity against most of NCI cancer cell lines. Among them, compound **6b** was the most effective analogue revealing an average growth inhibition of 40%, specifically against leukemia, NSCLC, colon, ovarian, and prostate cancers within the range of 51--85%. Further angiogenesis assay was conducted using HET-CAM to check the mortality and toxicity of the test compounds at 100 and 40 μM concentrations. Thirteen out of 21 test compounds were nontoxic for the chick embryos, and 7 of these compounds revealed a remarkable reduction of the blood vessels developed including compound **6b** as the most effective angiogenic agents. Therefore, compound **6b** was subjected for VEGFR-2, PDGFR, and C-Met kinase inhibitory assays to exhibit submicromolar inhibitory activities of IC~50~ 435, 371, and 654 nM, respectively. Docking of compound **6b** inside the active site of both c-Met kinase and VEFGR2 showed the crucial role of the oxindole moiety as it revealed a hydrogen bond with Met1160 (2.16 Å) in c-Met kinase active site and hydrogen bond with D1222 in the VEGFR2 active site.

4. Experimental Section {#sec4}
=======================

4.1. Chemistry {#sec4.1}
--------------

### 4.1.1. General {#sec4.1.1}

The Bruker spectrometer was used to record the proton magnetic resonance ^1^H NMR, ^13^C NMR, and ^13^C DEPT135 at 300 MHz and 75 MHz. DMSO-*d*~6~ was used as a solvent to generate all NMR spectra. The strong peak of DMSO at δ 2.50 was used for spectral calibration. The coupling constants are expressed in Hz. Both protons of NH and OH protons were measured as D~2~O exchangeable. The chemical shifts were expressed in values (ppm). The coupling constant (*J*) is given in hertz (Hz). The abbreviations used are as follows: s, singlet; d, doublet; and m, multiplet. High-resolution mass spectrometry (HRMS) was performed at Campus Chemical Instrument Center (CCIC) Mass Spectrometry and Proteomics Facility at The Ohio State University, USA. Melting points (mp) were measured with a Stuart melting point apparatus and were uncorrected. Thin-layer chromatography using precoated glass plates silica gel plates of 60F254-Merck was used for monitoring the progress of reactions, and our fluorescent products were visualized by a UV lamp.

### 4.1.2. General Procedures for the Preparation of (6-Aryl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)-hydrazine Hydrochloride (**5a--d**) {#sec4.1.2}

Purpald (**4**; 2.92 g, 20 mmol, 1.1 equiv) was added to a stirred solution of 30 mL of 1 N HCl. The mixture was heated whereby a clear solution is obtained, and then a solution of 2′-bromoacetophenone (**3**; 18 mmol, 1.0 equiv) in 30 mL of ethanol was added dropwise over 10 min. Heating of the reaction mixture was continued for another 50 min. The reaction mixture was then left to cool unstirred for 2--3 h, whereby a precipitate of **5** is formed. The formed precipitate was suction filtered, washed with 10 mL of ice-cold water, and dried. The crude product **5** was used without further purification.

#### 4.1.2.1. 2-(6-Phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazin-1-ium Chloride (**5a**) {#sec4.1.2.1}

Yield 3.87 g (76%) of yellowish-white powder; mp 205--206 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 10.19 (2H, br s, D~2~O exchangeable, 3-NH), 8.11 (2H, br s, Ar-2′,6′-H), 7.61 (3H, br s, Ar-3′,4′,5′-H), 4.49 (2H, s, 7-CH~2~). ^13^C NMR (125 MHz, DMSO): δ 154.99 (1C, 6-*C*), 151.38 (1C, 8a-*C*), 137.56 (1C, 3-*C*), 132.25 (1C, Ar-1′-*C*), 129.97 (2C, Ar-2′,6′-*C*H), 129.58 (3C, Ar-3′,4′,5′-*C*H), 23.26 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.97 (2C, Ar-2′,6′-*C*H), 129.58 (3C, Ar-3′,4′,5′-*C*H), 23.26 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~10~H~11~N~6~S \[M + H\]^+^, 247.0766; found, 247.0763.

#### 4.1.2.2. 2-(6-(*p*-Tolyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazin-1-ium Chloride (**5b**) {#sec4.1.2.2}

Yield 4.2 g (79%) of yellowish-white powder; mp 225--226 ^o^; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 9.21 (2H, br s, D~2~O exchangeable, 3-NH-NH~2~), 9.21 (1H, br s, D~2~O exchangeable, 3-NH), 7.98 (2H, dd, *J* = 7.3 Hz, Ar-2′,6′-H), 7.39 (2H, br s, Ar-3′,5′-H), 4.43--4.50 (2H, br s, 7-CH~2~), 2.40 (3H, s, 5′-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 154.99 (1C, 6-*C*), 151.38 (1C, 8a-*C*), 137.56 (1C, 3-*C*), 132.25 (1C, Ar-1′-*C*), 129.97 (2C, Ar-2′,6′-*C*H), 129.58 (3C, Ar-3′,4′,5′-*C*H), 23.26 (1C, 7-*C*H). DEPT C^135^ (125 MHz, DMSO): δ 129.97 (2C, Ar-2′,6′-*C*H), 129.58 (3C, Ar-3′,4′,5′-*C*H), 23.26 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~11~H~13~N~6~S \[M+1\]^+^, 261.0922; found, 261.0918.

#### 4.1.2.3. 2-(6-(4-Methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazin-1-ium Chloride (**5c**) {#sec4.1.2.3}

Yield 4.4 g (78%) of yellowish-white powder; mp 209--210 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 9.17 (1H, br s, D~2~O exchangeable, 3-NH), 7.95--8.10 (2H, dd, *J* = 37.0, 8.8 Hz, Ar-2′,6′-H), 7.61 (3H, d, *J* = 8.8 Hz, Ar-3′,5′-H), 4.45 (2H, s, 7-CH~2~), 3.86 (3H, s, 5′-OC*H*~3~). ^13^C NMR (125 MHz, DMSO): δ 163.01 (1C, 6-*C*), 161.44 (1C, Ar-4′-*C*), 155.85 (1C, 8a-*C*), 151.15 (1C, 3-*C*), 130.15 (2C, Ar-2′,6′-*C*H), 125.35 (1C, Ar-1′-*C*), 114.90 (2C, Ar-3′, 5′-*C*H), 56.09 (1C, 5′-O*C*H~3~), 23.17 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 130.15 (2C, Ar-2′,6′-*C*H), 114.90 (2C, Ar-3′, 5′-*C*H), 56.09 (1C, 5′-O*C*H~3~), 23.17 (C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~11~H~13~N~6~OS \[M + H\]^+^, 277.0872; found, 277.0865.

#### 4.1.2.4. 2-(6-(4-Chloro-phenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)-hydrazine Hydrochloride (**5d**) {#sec4.1.2.4}

Yield 4.6 g (81%) of yellowish-white powder; mp 184--185 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 9.18 (1H, br s, D~2~O exchangeable, 3-NH), 9.05 (1H, br s, D~2~O exchangeable, 3-NH-NH~2~), 8.13 (2H, d, *J* = 8.5 Hz, Ar-2′,6′-H), 7.68 (2H, d, *J* = 8.5 Hz, Ar-3′,5′-H), 4.47 (2H, s, 7-CH~2~). ^13^C NMR (125 MHz, DMSO): δ 154.99 (1C, 6-*C*), 151.38 (1C, 8a-*C*), 139.70 (1C, 3-*C*), 137.56 (2C, Ar-4′-*C*), 132.25 (1C, Ar-1′-*C*), 129.97 (2C, Ar-3,5′-*C*H), 129.58 (2C, Ar-2′,6′-*C*H), 23.26 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.97 (2C, Ar-3,5′-*C*H), 129.58 (2C, Ar-2′,6′-*C*H), 23.26 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~10~H~10~ClN~6~S \[M+1\]^+^, 281.0376; found, 281.0367.

### 4.1.3. General Procedure for the Synthesis of Compound **6a--y** {#sec4.1.3}

A mixture of the appropriate isatin (**2**; 1.0 mmol, 1.0 equiv) and appropriate compound (**5**; 1.3 mmol, 1.3 equiv) in ethanol (5 mL) was heated under reflux for 1 h. The reaction mixture was cooled to room temperature, and the crude product was filtered off, washed, and dried. The crude product was recrystallized from the DMF/H~2~O mixture (5:1).

#### 4.1.3.1. 3-(2-(6-Phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)indolin-2-one (**6a**) {#sec4.1.3.1}

Yield 304 mg (81%) of yellowish white powder; mp 284--285 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.30 (1H, br s, D~2~O exchangeable, 3-NH), 11.26 (1H, br s, D~2~O exchangeable, 1″-NH), 8.05 (2H, d, *J* = 6.3 Hz, Ar-2′,6′-H), 7.71--7.59 (3H, m, Ar-3′,4′,5′-H), 7.56 (1H, d, *J* = 7.7 Hz, Ar-4″-H), 7.36 (1H, t, *J* = 7.7 Hz, Ar-6″-H), 7.11 (1H, t, *J* = 7.7 Hz, Ar-5″-H), 6.98 (1H, d, *J* = 7.7 Hz, Ar-7″-H), 4.48 (2H, s, 7-CH~2~). ^13^C NMR (125 MHz, DMSO): δ 163.88 (1C, 2″-*C*=O), 159.36 (1C, 6-*C*), 155.37 (1C, 8a-*C*), 149.48 (1C, 3-*C*), 141.74 (1C, 7″a-*C*), 134.32 (1C, Ar-1′-*C*), 133.61 (1C, 3″-*C*), 132.57 (1C, 6″-*C*H), 131.00 (1C, Ar-4′-*C*H), 129.60 (2C, Ar-3,5′-*C*H), 127.79 (2C, Ar-2′,6′-*C*H), 127.66 (1C, 4″-*C*H), 122.99 (1C, 5″-*C*H), 120.41 (1C, 3″a-*C*), 111.56 (1C, 7″-*C*H), 23.78 (2C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 132.57 (1C, 6″-*C*H), 131.01 (1C, Ar-4′-*C*H), 129.60 (2C, Ar-3,5′-*C*H), 127.79 (2C, Ar-2′,6′-*C*H), 127.66 (1C, 4″-*C*H), 122.99 (1C, 5″-*C*H), 120.50 ? 111.56 (1C, 7″-*C*H), 23.78 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~18~H~14~N~7~OS \[M + H\]^+^, 376.0981; found, 376.0976.

#### 4.1.3.2. 5-Methoxy-3-(2-(6-phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineylidene)indolin-2-one (**6b**) {#sec4.1.3.2}

Yield 357 mg (88%) of yellowish-white powder; mp 223 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.34 (1H, br s, D~2~O exchangeable, 3-NH), 11.06 (1H, br s, D~2~O exchangeable, 1″-NH), 8.05 (2H, d, *J* = 6.3 Hz, Ar-2′,6′-H), 7.70--7.48 (3H, m, Ar-3′,4′,5′-H), 7.10 (1H, s, Ar-4″-H), 6.95--6.86 (1H, m Ar-7″-H), 6.83--6.66 (1H, m, Ar-6″-H), 4.47 (2H, s, 7-CH~2~), 3.78 (3H, s, 6″-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 164.00 (1C, 2″-*C*=O), 155.79 (1C, 6-*C*), 155.37 (1C, 8a-*C*), 154.72 (1C, 3-*C*), 149.46 (1C, 7″a-*C*), 135.42 (1C, Ar-1′-*C*), 134.60 (1C, 3″-*C*), 132.56 (1C, Ar-4′-*C*H), 129.59 (2C, Ar-3,5′-*C*H), 127.79 (2C, Ar-2′,6′-*C*H), 121.14 (1C, 3″a-*C*), 117.39 (1C, 7″-*C*H), 112.41 (1C, 4″-*C*H), 105.28 (1C, 6″-*C*H), 56.02 (1C, 5″-O*C*H~3~), 23.77 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 132.57 (1C, Ar-4′-*C*H), 129.59 (2C, Ar-3,5′-*C*H), 127.79 (2C, Ar-2′,6′-*C*H), 117.39 (1C, 7″-*C*H), 112.41 (1C, 4″-*C*H), 105.28 (1C, 6″-*C*H), 56.02 (1C, 5″-O*C*H~3~), 23.76 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~19~H~16~N~7~O~2~S \[M + H\]^+^, 406.1086; found, 406.1082.

#### 4.1.3.3. 3-(2-(6-(*p*-Tolyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)-indolin-2-one (**6c**) {#sec4.1.3.3}

Yield 362 mg (93%) of yellowish-white powder; mp 292--293 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.29 (1H, br s, D~2~O exchangeable, 3-NH), 11.25 (1H, br s, D~2~O exchangeable, 1″-NH), 7.95 (2H, d, *J* = 7.90 Hz, Ar-2′,6′-H), 7.56 (1H, d, *J* = 7.50 Hz, Ar-4″-H), 7.46--7.31 (3H, m, Ar-3′,5′, 6″-H), 7.11 (1H, t, *J* = 7.50 Hz, Ar-5″-H), 6.98 (1H, d, *J* = 7.50 Hz, Ar-7″-H), 4.44 (2H, s, 7-CH~2~), 2.40 (3H, s, 4′-CH~3~).

^13^C NMR (125 MHz, DMSO): δ 163.88 (1C, 2″-*C*=O), 155.27 (1C, 6-*C*), 154.74 (1C, 8a-*C*), 149.42 (1C, 3-*C*), 142.88 (1C, 7″a-*C*), 141.72 (1C, Ar-4′-*C*), 138.37 (1C, 3″-*C*), 134.24 (1C, Ar-1′-*C*), 130.97 (1C, 6″-*C*H), 130.75 (1C, 4″-*C*H), 130.18 (2C, Ar-3,5′-*C*H), 127.75 (2C, Ar-2′,6′-*C*H), 127.62 (1C, 4″-*C*H), 122.99 (1C, 5″-*C*H), 120.43 (1C, 3″a-*C*), 111.55 (1C, 7″-*C*H), 23.64 (1C, 7-*C*H~2~), 21.53 (1C, 4′-*C*H~3~). DEPT C^135^ (125 MHz, DMSO): δ 130.97 (1C, 6″-*C*H), 130.18 (2C, Ar-3,5′-*C*H), 127.75 (2C, Ar-2′,6′-*C*H), 127.62 (1C, 4″-*C*H), 122.98 (1C, 5″-*C*H), 120.48 (1C, 3″a-*C*), 111.55 (1C, 7″-*C*H), 23.64 (1C, 7-*C*H~2~), 21.53 (1C, 4′-*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~19~H~16~N~7~OS \[M + H\]^+^, 390.1137; found, 390.1130.

#### 4.1.3.4. 5-Methoxy-3-(2-(6-(*p*-tolyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ylidene)indolin-2-one (**6d**) {#sec4.1.3.4}

Yield 356 mg (85%) of yellowish-white powder; mp 282 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.33 (1H, br s, D~2~O exchangeable, 3-NH), 11.06 (1H, br s, D~2~O exchangeable, 1″-NH), 7.94 (2H, d, *J* = 7.70 Hz, Ar-2′,6′-H), 7.44--7.32 (2H, m, Ar-3′,5′-H), 7.09 (1H, s, Ar-4″-H), 6.77 (1H, dd, *J* = 19.0, 9.01 Hz, 6″-H), 6.97--6.85 (1H, m, Ar-7″-H), 4.44 (2H, s, 7-CH~2~), 3.78 (3H, s, 5″-OCH~3~), 2.40 (3H, s, 4′-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 164.01 (1C, 2″-*C*=O), 155.78 (1C, 6-*C*), 155.26 (1C, 5″-*C*), 154.74 (1C, 8a-*C*), 149.40 (1C, 3-*C*), 142.87 (1C, 7″a-*C*), 141.25 (1C, Ar-4′-*C*), 138.88 (1C, 3″-*C*), 135.41 (1C, Ar-1′-*C*), 130.17 (2C, Ar-3,5′-*C*H), 127.75 (2C, Ar-2′,6′-*C*H), 123.90 (1C, 3″a-*C*), 117.35 (1C, 7″-*C*H), 112.39 (1C, 6″-*C*H), 105.28 (1C, 4″-*C*H), 56.02 (1C, 5″-O*C*H~3~), 23.64 (1C, 7-*C*H~2~), 21.53 (1C, 4′-*C*H~3~). DEPT C^135^ (125 MHz, DMSO): δ 130.17 (2C, Ar-3,5′-*C*H), 127.75 (2C, Ar-2′,6′-*C*H), 117.34 (1C, 7″-*C*H), 112.38 (1C, 6″-*C*H), 105.27 (1C, 4″-*C*H), 56.01 (1C, 5″-O*C*H~3~), 23.63 (1C, 7-*C*H~2~), 21.53 (1C, 4′-*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~20~H~18~N~7~O~2~S \[M + H\]^+^, 420.1243; found, 420.1241.

#### 4.1.3.5. 3-(2-(6-(4-Chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineylidene)indolin-2-one (**6e**) {#sec4.1.3.5}

Yield 377 mg (92%) of yellowish-white powder; mp 295 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.28 (1H, br s, D~2~O exchangeable, 3-NH), 11.24 (1H, br s, D~2~O exchangeable, 1″-NH), 8.06 (2H, br s, Ar-2′,6′-H), 7.72 (3H, m, Ar-3′,5′-H), 7.36 (1H, br s, Ar-4″-H), 7.28--7.07 (1H, m, Ar-7″-H), 7.00 (1H, br s, Ar-6″-H), 6.84 (1H, br s, Ar-5″-H), 4.45 (2H, s, 7-CH~2~). ^13^C NMR (125 MHz, DMSO): δ 164.00 (1C, 2″-*C*=O), 155.79 (1C, 6-*C*), 155.37 (1C, 8a-*C*), 154.72 (1C, 3-*C*), 149.46 (1C, 7″a-*C*), 135.42 (1C, Ar-1′-*C*), 134.60 (1C, 3″-*C*), 132.56 (1C, Ar-4′-*C*H), 129.59 (2C, Ar-3,5′-*C*H), 127.79 (2C, Ar-2′,6′-*C*H), 121.14 (1C, 3″a-*C*), 117.39 (1C, 7″-*C*H), 112.41 (1C, 4″-*C*H), 105.28 (1C, 6″-*C*H), 56.02 (1C, 5″-O*C*H~3~), 23.77 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 132.57 (1C, Ar-4′-*C*H), 129.59 (2C, Ar-3,5′-*C*H), 127.79 (2C, Ar-2′,6′-*C*H), 117.39 (1C, 7″-*C*H), 112.41 (1C, 4″-*C*H), 105.28 (1C, 6″-*C*H), 56.02 (1C, 5″-O*C*H~3~), 23.76 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~18~H~13~ClN~7~OS \[M + H\]^+^, 410.0591; found, 410.0593.

#### 4.1.3.6. 3-(2-(6-(4-Chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazine-eylidene)-5-methoxyindolin-2-one (**6f**) {#sec4.1.3.6}

Yield 396 mg (90%) of yellowish-white powder; mp 292 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.31 (1H, br s, D~2~O exchangeable, 3-NH), 11.04 (1H, br s, D~2~O exchangeable, 1″-NH), 8.23 (2H, br s, Ar-2′,6′-H), 8.02 (2H, br s, Ar-3′,5′-H), 7.07 (1H, s, Ar-4″-H), 6.98--6.20 (2H, m, 6″ and 7″-H), 4.44 (2H, s, 7-CH~2~), 3.75 (3H, s, 5″-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 163.97 (1C, 2″-*C*=O), 161.40 (1C, 5″-*C*), 155.77 (1C, 6-*C*), 154.31 (1C, 8a-*C*), 149.42 (1C, 3-*C*), 137.41 (1C, 7″a-*C*), 135.42 (1C, Ar-4′-*C*), 133.02 (1C, 3″-*C*), 132.46 (1C, Ar-1′-*C*), 129.68 (2C, Ar-3,5′-*C*H), 129.50 (2C, Ar-2′,6′-*C*H), 124.46 (1C, 3″a-*C*), 117.39 (1C, 7″-*C*H), 112.38 (1C, 6″-*C*H), 105.29 (1C, 4″-*C*H), 56.01 (1C, 5″-O*C*H~3~), 23.68 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.70 (2C, Ar-3,5′-*C*H), 129.51 (2C, Ar-2′,6′-*C*H), 117.39 (1C, 7″-*C*H), 112.39 (1C, 6″-*C*H), 105.29 (1C, 4″-*C*H), 56.01 (1C, 5″-O*C*H~3~), 23.68 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~19~H~15~ClN~7~O~2~S \[M + H\]^+^, 440.0696; found, 440.0691.

#### 4.1.3.7. 3-(2-(6-(4-Methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineylidene)indolin-2-one (**6g**) {#sec4.1.3.7}

Yield 361 mg (88%) of yellowish-white powder; mp 293 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.28 (1H, br s, D~2~O exchangeable, 3-NH), 11.23 (1H, br s, D~2~O exchangeable, 1″-NH), 8.02 (2H, d, *J* = 8.7 Hz, Ar-2′,6′-H), 7.56 (1H, d, *J* = 7.5 Hz, Ar-4″-H), 7.35 (1H, t, *J* = 7.7 Hz, Ar-6″-H), 7.20--7.08 (3H, m, Ar-3′,5′,5″-H), 6.98 (1H, d, *J* = 7.7 Hz, Ar-5″-H), 6.98 (1H, d, *J* = 7.7 Hz, Ar-7″-H), 4.43 (2H, s, 7-CH~2~), 3.86 (3H, s, 4′-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 163.87 (1C, 2″-*C*=O), 162.86 (1C, 6-*C*), 154.93 (1C, 8a-*C*), 149.36 (1C, 3-*C*), 141.69 (1C, 7″a-*C*), 138.33 (1C, Ar-4′-*C*), 134.15 (1C, 3″-*C*), 130.93 (1C, 6″-*C*H), 129.67 (2C, Ar-2′,6′-*C*H), 129.49 (1C, Ar-1′-*C*), 125.64 (1C, 3″a-*C*), 122.97 (1C, 4″-*C*H), 120.45 (1C, 5″-*C*H), 115.04 (2C, Ar-3′,5′-*C*H), 111.54 (1C, 7″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 23.56 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 130.93 (1C, 6″-*C*H), 129.67 (2C, Ar-2′,6′-*C*H), 122.97 (1C, 4″-*C*H), 120.45 (1C, 5″-*C*H), 115.04 (2C, Ar-3,5′-*C*H), 111.54 (1C, 7″-*C*H), 56.06 (1C, 4′-O*C*H~3~), 23.55 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~19~H~16~N~7~O~2~S \[M + H\]^+^, 406.1086; found, 406.1082.

#### 4.1.3.8. 3-(2-(6-(4-Methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineylidene)-5-methylindolin-2-one (**6h**) {#sec4.1.3.8}

Yield 364 mg (87%) of yellowish-white powder; mp 283--284 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.26 (1H, br s, D~2~O exchangeable, 3-NH), 11.12 (1H, br s, D~2~O exchangeable, 1″-NH), 8.01 (2H, d, *J* = 8.4 Hz, Ar-2′,6′-H), 7.37 (1H, s, Ar-4″-H), 7.24--7.05 (3H, m, Ar-3′,5′,6″-H), 6.86 (1H, d, *J* = 7.9 Hz, Ar-7″-H), 4.42 (2H, s, 7-CH~2~), 3.86 (3H, s, 4′-OCH~3~), 2.31 (3H, s, 5″-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 163.94 (1C, 2″-*C*=O), 162.84 (1C, 6-*C*), 154.87 (1C, 8a-*C*), 149.38 (1C, 3-*C*), 139.45 (1C, 7″a-*C*), 138.27 (1C, Ar-4′-*C*), 134.26 (1C, 3″-*C*), 131.37 (1C, 6″-*C*H), 129.66 (2C, Ar-2′,6′-*C*H), 129.37 (1C, Ar-1′-*C*), 125.64 (1C, 3″a-*C*), 120.83 (1C, 4″-*C*H), 115.02 (2C, Ar-3,5′-*C*H), 111.29 (1C, 7″-*C*H), 56.04 (1C, 4′-O*C*H~3~), 23.54 (1C, 7-*C*H~2~), 21.08 (1C, 5″-*C*H~3~). DEPT C^135^ (125 MHz, DMSO): δ 131.37 (1C, 6″-*C*H), 129.66 (2C, Ar-2′,6′-*C*H), 120.82 (1C, 4″-*C*H), 115.02 (2C, Ar-3,5′-*C*H), 111.29 (1C, 7″-*C*H), 56.04 (1C, 4′-O*C*H~3~), 23.53 (1C, 7-*C*H~2~), 21.08 (1C, 5″-*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~20~H~18~N~7~O~2~S \[M + H\]^+^, 420.1243; found, 420.1238.

#### 4.1.3.9. 3-(2-(6-(4-Methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineyl-idene)-5,7-dimethylindolin-2-one (**6i**) {#sec4.1.3.9}

Yield 381 mg (88%) of yellowish-white powder; mp 233 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.46 (1H, br s, D~2~O exchangeable, 3-NH), 11.24 (1H, br s, D~2~O exchangeable, 1″-NH), 8.02 (2H, d, *J* = 8.7 Hz, Ar-2′,6′-H), 7.19--7.08 (3H, m, Ar-3′,5′,4″-H), 6.98 (1H, s, Ar-6″-H), 4.46 (2H, s, 7-CH~2~), 3.86 (3H, s, 4′-OCH~3~), 2.26 (3H, s, 5″-CH~3~), 2.19 (3H, s, 7″-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 163.03 (1C, 2″-*C*=O), 162.61 (1C, 6-*C*), 155.59 (1C, 8a-*C*), 147.57 (1C, 3-*C*), 140.52 (1C, 7″a-*C*), 138.42 (1C, Ar-4′-*C*), 135.90 (1C, 3″-*C*), 133.28 (1C, 7″-*C*), 132.02 (1C, 5″-*C*), 130.19 (1C, 6″-*C*H), 129.78 (2C, Ar-2′,6′-*C*H), 129.39 (1C, Ar-1′-*C*), 125.41 (1C, 4″-*C*H), 124.25 (1C, 3″a-*C*), 114.91 (2C, Ar-3,5′-*C*H), 56.09 (1C, 4′-O*C*H~3~), 23.54 (1C, 7-*C*H~2~), 20.98 (1C, 5″-*C*H~3~), 16.37 (1C, 7″-*C*H~3~). DEPT C^135^ (125 MHz, DMSO): δ 129.78 (2C, Ar-2′,6′-*C*H), 125.48 (1C, 4″-*C*H), 130.17 (1C, 6″-*C*H), 114.91 (2C, Ar-3,5′-*C*H), 56.08 (1C, 4′-O*C*H~3~), 23.54 (1C, 7-*C*H~2~), 20.98 (1C, 5″-*C*H~3~), 16.37 (1C, 7″-*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~21~H~20~N~7~O~2~S \[M + H\]^+^, 434.1399; found, 434.1396.

#### 4.1.3.10. 5-Fluoro-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl) hydrazineylidene)indolin-2-one (**6j**) {#sec4.1.3.10}

Yield 360 mg (85%) of yellowish-white powder; mp 288--289 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.32 (1H, br s, D~2~O exchangeable, 3-NH), 11.24 (1H, br s, D~2~O exchangeable, 1″-NH), 8.09--7.98 (2H, m, Ar-2′,6′-H), 7.35 (1H, d, *J* = 8.0 Hz, Ar-7″-H), 7.24--7.03 (3H, m, Ar-3′,5′,4″-H), 7.02--6.93 (1H, d, *J* = 7.9 Hz, Ar-6″-H), 4.43 (2H, s, 7-CH~2~), 3.87 (3H, s, 4′-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 164.03 (1C, 2″-*C*=O), 162.88 (1C, 6-*C*), 155.08 (1C, 8a-*C*), 149.16 (1C, 3-*C*), 139.32 (1C, 7″a-*C*), 137.90 (1C, Ar-4′-*C*), 133.69 (1C, 3″-*C*), 129.68 (2C, Ar-2′,6′-*C*H), 126.18 (1C, Ar-1′-*C*), 125.59 (1C, 3″a-*C*), 129.68 (2C, Ar-2′,6′-*C*H), 115.03 (2C, Ar-3,5′-*C*H), 112.65 (1C, 7″-*C*H), 110.33 (1C, 4″-*C*H), 107.63 (1C, 6″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 23.55 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.68 (2C, Ar-2′,6′-*C*H), 115.03 (2C, Ar-3,5′-*C*H), 112.55 (1C, 7″-*C*H), 110.32 (1C, 4″-*C*H), 107.63 (1C, 6″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 23.54 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~19~H~15~FN~7~O~2~S \[M + H\]^+^, 424.0992; found, 424.0989.

#### 4.1.3.11. 7-Fluoro-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)indolin-2-one (**6k**) {#sec4.1.3.11}

Yield 381 g (90%) of yellowish-white powder; mp 288--290 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.32 (1H, br s, D~2~O exchangeable, 3-NH), 11.24 (1H, br s, D~2~O exchangeable, 1″-NH), 8.09--7.98 (2H, m, Ar-2′,6′-H), 7.35 (1H, d, *J* = 8.0 Hz, Ar-7″-H), 7.24--7.03 (3H, m, Ar-3′,5′,4″-H), 7.02--6.93 (1H, d, *J* = 7.9 Hz, Ar-6″-H), 4.43 (2H, s, 7-CH~2~), 3.87 (3H, s, 4′-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 164.03 (1C, 2″-*C*=O), 162.88 (1C, 6-*C*), 155.08 (1C, 8a-*C*), 149.16 (1C, 3-*C*), 139.32 (1C, 7″a-*C*), 137.90 (1C, Ar-4′-*C*), 133.69 (1C, 3″-*C*), 129.68 (2C, Ar-2′,6′-*C*H), 126.18 (1C, Ar-1′-*C*), 125.59 (1C, 3″a-*C*), 129.68 (2C, Ar-2′,6′-*C*H), 115.03 (2C, Ar-3,5′-*C*H), 112.65 (1C, 7″-*C*H), 110.33 (1C, 4″-*C*H), 107.63 (1C, 6″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 23.55 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.68 (2C, Ar-2′,6′-*C*H), 115.03 (2C, Ar-3,5′-*C*H), 112.55 (1C, 7″-*C*H), 110.32 (1C, 4″-*C*H), 107.63 (1C, 6″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 23.54 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~19~H~15~FN~7~O~2~S \[M + H\]^+^, 424.0992; found, 424.0989.

#### 4.1.3.12. 5-Chloro-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)indolin-2-one (**6l**) {#sec4.1.3.12}

Yield 440 mg (85%) of yellowish-white powder; mp 293--295 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.27 (1H, br s, D~2~O exchangeable, 3-NH), 11.35 (1H, br s, D~2~O exchangeable, 1″-NH), 8.72 (1H, s, Ar-4″-H), 8.06 (2H, d, *J* = 8.0 Hz, Ar-2′,6′-H), 7.25 (1H, d, *J* = 8.0 Hz, Ar-7″-H), 7.13--7.08 (2H, m, Ar-3′,5′-H), 6.84 (1H, d, *J* = 8.0 Hz, Ar-6″-H), 4.45 (2H, s, 7-CH~2~), 3.87 (3H, s, 4′-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 163.70 (1C, 2″-*C*=O), 161.93 (1C, 6-*C*), 154.61 (1C, 8a-*C*), 147.43 (1C, 3-*C*), 142.29 (1C, Ar-4′-*C*), 140.30 (1C, 7″a-*C*), 134.58 (1C, 3″-*C*), 132.90 (1C, 5″-*C*), 129.52 (2C, Ar-2′,6′-*C*H), 128.84 (1C, Ar-1′-*C*), 126.57 (1C, 6″-*C*H), 125.47 (1C, 3″a-*C*), 123.70 (1C, 4″-*C*H), 114.89 (2C, Ar-3,5′-*C*H), 111.02 (1C, 7″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 22.61 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.51 (2C, Ar-2′,6′-*C*H), 126.49 (1C, 6″-*C*H),123.59 (1C, 4″-*C*H), 114.87 (2C, Ar-3,5′-*C*H), 111.01 (1C, 7″-*C*H), 56.03 (1C, 4′-O*C*H~3~), 22.57 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~19~H~15~ClN~7~O~2~S \[M + H\]^+^, 440.0696; found, 440.0698.

#### 4.1.3.13. 5-Bromo-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)indolin-2-one (**6m**) {#sec4.1.3.13}

Yield 416 mg (86%) of yellowish-white powder; mp 297--298 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.25 (1H, br s, D~2~O exchangeable, 3-NH), 11.34 (1H, br s, D~2~O exchangeable, 1″-NH), 8.87 (1H, s, Ar-4″-H), 8.12 (2H, d, *J* = 8.5 Hz, Ar-2′,6′-H), 7.38 (1H, d, *J* = 8.2 Hz, Ar-7″-H), 7.16--7.05 (2H, m, Ar-3′,5′-H), 6.80 (1H, d, *J* = 8.2 Hz, Ar-6″-H), 4.45 (2H, s, 7-CH~2~), 3.87 (3H, s, 4′-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 166.12 (1C, 2″-*C*=O), 162.74 (1C, 6-*C*), 154.85 (1C, 8a-*C*), 154.62 (1C, 3-*C*), 140.73 (1C, Ar-4′-*C*), 139.22 (1C, 7″a-*C*), 135.01 (1C, 3″-*C*), 131.62 (1C, 6″-*C*H), 129.55 (2C, Ar-2′,6′-*C*H), 129.36 (1C, Ar-1′-*C*), 125.97 (1C, 3″a-*C*), 123.54 (1C, 4″-*C*H), 114.96 (2C, Ar-3,5′-*C*H), 113.33 (1C, 5″-*C*), 111.55 (1C, 7″-*C*H), 56.06 (1C, 4′-O*C*H~3~), 22.57 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 131.63 (1C, 6″-*C*H), 129.57 (2C, Ar-2′,6′-*C*H), 123.65 (1C, 4″-*C*H), 115.03 (2C, Ar-3,5′-*C*H), 111.58 (1C, 7″-*C*H), 56.07 (1C, 4′-O*C*H~3~), 22.59 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~19~H~15~BrN~7~O~2~S \[M + H\]^+^, 484.0191; found, 484.0196.

#### 4.1.3.14. 5-Methoxy-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)indolin-2-one (**6n**) {#sec4.1.3.14}

Yield 370 mg (85%) of yellowish-white powder; mp 278--280 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.34 (1H, br s, D~2~O exchangeable, 3-NH), 11.05 (1H, br s, D~2~O exchangeable, 1″-NH), 8.02 (2H, d, *J* = 8.6 Hz, Ar-2′,6′-H), 7.21--7.03 (3H, m, Ar-3′,5′, 4″-H), 6.97--6.84 (1H, m, Ar-7″-H), 6.81--6.66 (1H, m, Ar-6″-H), 4.43 (2H, s, 7-CH~2~), 3.87 (3H, s, 4′-OCH~3~), 3.78 (3H, s, 6″-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 168.19 (1C, 2″-*C*=O), 163.88 (1C, 6-*C*), 157.54 (1C, 8a-*C*), 155.78 (1C, 3-*C*), 140.74 (1C, Ar-4′-*C*), 135.78 (1C, 7″a-*C*), 135.38 (1C, 3″-*C*), 130.63 (1C, 5″-*C*), 129.67 (2C, Ar-2′,6′-*C*H), 129.38 (1C, Ar-1′-*C*), 125.63 (1C, 3″a-*C*), 123.75 (1C, 7″-*C*H), 117.34 (1C, 6″-*C*H), 115.04 (2C, Ar-3,5′-*C*H), 114.82 (1C, 4″-*C*H), 56.03 (1C, 4′-O*C*H~3~), 55.65 (1C, 5″-O*C*H~3~), 23.55 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.68 (2C, Ar-2′,6′-*C*H), 123.81 (1C, 7″-*C*H), 117.35 (1C, 6″-*C*H), 115.04 (2C, Ar-3,5′-*C*H), 114.82 (1C, 4″-*C*H), 56.02 (1C, 4′-O*C*H~3~), 55.64 (1C, 5″-O*C*H~3~), 23.54 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~20~H~18~N~7~O~3~S \[M + H\]^+^, 436.1192; found, 436.1194.

#### 4.1.3.15. 3-(2-(6-(4-Methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineylidene)-5-(trifluoromethoxy)indolin-2-one (**6o**) {#sec4.1.3.15}

Yield 406 mg (83%) of yellowish-white powder; mp 284--285 °C (decompo.); ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.28 (1H, br s, D~2~O exchangeable, 3-NH), 11.42 (1H, br s, D~2~O exchangeable, 1″-NH), 8.60 (1H, s, Ar-4″-H), 8.12--7.97 (2H, m, Ar-2′,6′-H), 7.21 (1H, d, *J* = 8.3 Hz, Ar-7″-H), 7.06 (2H, d, *J* = 8.3 Hz, Ar-3′,5′-H), 6.90 (1H, d, *J* = 8.3 Hz, Ar-6″-H), 4.45 (2H, s, 7-CH~2~), 3.86 (3H, s, 4′-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 168.46 (1C, 2″-*C*=O), 162.67 (1C, 6-*C*), 159.32 (1C, 5″-*C*), 155.10 (1C, 8a-*C*), 154.65 (1C, 3-*C*), 149.10 (1C, 5″-O*C*F~3~), 140.63 (1C, Ar-4′-*C*), 139.24 (1C, 3″-*C*), 135.27 (1C, 7″a-*C*), 129.41 (2C, Ar-2′,6′-*C*H), 124.14 (1C, Ar-1′-*C*), 123.36 (1C, 3″a-*C*), 122.53 (1C, 7″-*C*H), 119.76 (1C, 6″-*C*H), 114.65 (2C, Ar-3,5′-*C*H), 110.38 (1C, 4″-*C*H), 55.96 (1C, 4′-O*C*H~3~), 23.55 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.68 (2C, Ar-2′,6′-*C*H), 123.81 (1C, 7″-*C*H), 117.35 (1C, 6″-*C*H), 115.04 (2C, Ar-3,5′-*C*H), 114.82 (1C, 4″-*C*H), 56.02 (1C, 4′-O*C*H~3~), 55.64 (1C, 5″-O*C*H~3~), 23.54 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~20~H~18~N~7~O~3~S \[M + H\]^+^, 490.0909; found, 490.0916.

#### 4.1.3.16. 5-Bromo-3-(2-(6-(4-chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)indolin-2-one (**6p**) {#sec4.1.3.16}

Yield 420 mg (86%) of yellowish-white powder; mp 304--307 °C (decompo.); ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.21 (1H, br s, D~2~O exchangeable, 3-NH), 11.34 (1H, br s, D~2~O exchangeable, 1″-NH), 8.83 (1H, s, Ar-4″-H), 8.13 (2H, d, *J* = 8.5 Hz, Ar-2′,6′-H), 7.65 (2H, d, *J* = 8.5 Hz, Ar-3′,5′-H), 7.37 (1H, d, *J* = 8.2 Hz, Ar-7″-H), 6.78 (1H, d, *J* = 8.2 Hz, Ar-6″-H), 4.46 (2H, s, 7-CH~2~). ^13^C NMR (125 MHz, DMSO): δ 166.08 (1C, 2″-*C*=O), 162.78 (1C, 6-*C*), 154.85 (1C, 8a-*C*), 153.81 (1C, 3-*C*), 140.83 (1C, 7″a-*C*), 137.25 (1C, Ar-4′-*C*), 133.05 (1C, 3″-*C*), 132.73 (1C, Ar-1′-*C*), 131.76 (1C, 6″-*C*H), 129.61 (2C, Ar-3,5′-*C*H), 129.34 (2C, Ar-2′,6′-*C*H), 123.99 (1C, 3″a-*C*), 122.66 (1C, 4″-*C*H), 113.42 (1C, 5″-*C*), 111.61 (1C, 7″-*C*H), 22.64 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 131.76 (1C, 6″-*C*H), 129.62 (2C, Ar-3,5′-*C*H), 129.34 (2C, Ar-2′,6′-*C*H), 122.68 (1C, 4″-*C*H), 111.61 (1C, 7″-*C*H), 22.64 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~18~H~12~BrClN~7~OS \[M + 1\]^+^, 487.9696; found, 487.9697.

#### 4.1.3.17. 3-(2-(6-(4-Chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineeylidene)-5-methylindolin-2-one (**6q**) {#sec4.1.3.17}

Yield 348 mg (82%) of yellow-powder; mp 303--306 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.26 (1H, br s, D~2~O exchangeable, 3-NH), 11.13 (1H, br s, D~2~O exchangeable, 1″-NH), 8.03 (2H, d, *J* = 8.4 Hz, Ar-2′,6′-H), 7.68 (2H, d, *J* = 8.4 Hz, Ar-3′,5′-H), 7.35 (1H, s, Ar-4″-H), 7.14 (1H, d, *J* = 8.0 Hz, Ar-6″-H), 6.85 (1H, d, *J* = 8.0 Hz, Ar-7″-H), 4.45 (2H, s, 7-CH~2~), 2.30 (3H, s, 5″-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 164.78 (1C, 2″-*C*=O), 163.91 (1C, 6-*C*), 154.24 (1C, 8a-*C*), 153.21 (1C, 3-*C*), 139.51 (1C, 7″a-*C*), 138.16 (1C, Ar-4′-*C*), 132.46 (1C, 3″-*C*), 131.98 (1C, Ar-1′-*C*), 131.44 (1C, 6″-*C*H), 129.68 (2C, Ar-3,5′-*C*H), 129.50 (2C, Ar-2′,6′-*C*H), 120.86 (1C, 4″-*C*H), 120.39 (1C, 3″a-*C*), 111.30 (1C, 7″-*C*H), 23.66 (1C, 7-*C*H~2~), 21.08 (1C, 5″-*C*H~3~). DEPT C^135^ (125 MHz, DMSO): δ 131.44 (1C, 6″-*C*H), 129.69 (2C, Ar-3,5′-*C*H), 129.50 (2C, Ar-2′,6′-*C*H), 120.86 (1C, 4″-*C*H), 111.30 (1C, 7″-*C*H), 23.65 (1C, 7-*C*H~2~), 21.08 (1C, 5″-*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~19~H~15~ClN~7~OS \[M + H\]^+^, 424.0747; found, 424.0747.

#### 4.1.3.18. 5-Bromo-3-(2-(6-(*p*-tolyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineylidene)indolin-2-one (**6r**) {#sec4.1.3.18}

Yield 379 mg (81%) of yellow-powder; mp 318--320 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.25 (1H, br s, D~2~O exchangeable, 3-NH), 11.37 (1H, br s, D~2~O exchangeable, 1″-NH), 8.06 (2H, d, *J* = 8.0 Hz, Ar-2′,6′-H), 7.94 (1H, d, *J* = 8.0 Hz, 7″-H, overlapped with CDCl~3~ peak), 7.41 (2H, *J* = 8.0 Hz, Ar-3′,5′-H), 7.37 (1H, s, Ar-4″-H), 6.80 (1H,d, *J* = 8.3 Hz, Ar-6″-H), 4.46 (2H, s, 7-CH~2~), 2.41 (3H, s, 4′-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 166.18 (1C, 2″-*C*=O), 162.84 (1C, 6-*C*), 154.98 (2C, 8a-*C* and 3-*C*), 142.81 (1C, 7″a-*C*), 140.86 (1C, Ar-4′-*C*), 139.60 (1C, 3″-*C*), 131.75 (1C, 6″-*C*H), 131.04 (1C, Ar-1′-*C*), 130.25 (2C, Ar-3,5′-*C*H), 129.49 (1C, 4″-*C*H), 127.72 (2C, Ar-2′,6′-*C*H), 117.14 (1C, 3″a-*C*), 113.42 (1C, 5″-*C*), 111.67 (1C, 7″-*C*H), 22.66 (1C, 7-*C*H~2~), 21.57 (1C, 4′-*C*H~3~). DEPT C^135^ (125 MHz, DMSO): δ131.76 (1C, 6″-*C*H), 130.25 (2C, Ar-3,5′-*C*H), 129.49 (1C, 4″-*C*H), 127.71 (2C, Ar-2′,6′-*C*H), 111.67 (1C, 7″-*C*H), 22.66 (1C, 7-*C*H~2~), 21.57 (1C, 4′-*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~19~H~15~BrN~7~OS \[M + H\]^+^, 468.0242; found, 468.0239.

#### 4.1.3.19. 5-Methyl-3-(2-(6-(*p*-tolyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineylidene)indolin-2-one (**6s**) {#sec4.1.3.19}

Yield 327 mg (81%) of yellow powder; mp 295--297 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.27 (1H, br s, D~2~O exchangeable, 3-NH), 11.14 (1H, br s, D~2~O exchangeable, 1″-NH), 7.94 (2H, d, *J* = 8.1 Hz, Ar-3′,5′-H), 7.41 (2H, *J* = 8.1 Hz, Ar-2′,6′-H), 7.38 (1H, s, Ar-4″-H), 7.16 (1H, d, *J* = 8.0 Hz, 6″-H), 6.86 (1H,d, *J* = 7.9 Hz, Ar-7″-H), 4.44 (2H, s, 7-CH~2~), 2.40 (3H, s, 4′-CH~3~), 2.31 (3H, s, 5″-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 166.33 (1C, 2″-*C*=O), 163.96 (1C, 6-*C*), 155.28 (1C, 8a-*C*), 149.45 (1C, 3-*C*), 142.88 (1C, Ar-4′-*C*), 139.51 (1C, 3″-*C*), 138.36 (1C, 7″a-*C*), 134.43 (1C, 5″-*C*), 132.02 (1C, Ar-1′-*C*), 131.45 (1C, 6″-*C*H), 130.77 (1C, 3″a-*C*), 130.18 (2C, Ar-3,5′-*C*H), 127.76 (2C, Ar-2′,6′-*C*H), 120.87 (1C, 4″-*C*H), 111.33 (1C, 7″-*C*H), 23.65 (1C, 7-*C*H~2~), 21.54 (1C, 4′-*C*H~3~), 21.09 (1C, 5″-*C*H~3~). DEPT C^135^ (125 MHz, DMSO): δ131.44 (1C, 6″-*C*H), 130.17 (2C, Ar-3,5′-*C*H), 127.75 (2C, Ar-2′,6′-*C*H), 120.86 (1C, 4″-*C*H), 111.33 (1C, 7″-*C*H), 23.64 (1C, 7-*C*H~2~), 21.53 (1C, 4′-*C*H~3~), 21.09 (1C, 5″-*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~20~H~18~N~7~OS \[M + H\]^+^, 404.1294; found, 404.1295.

#### 4.1.3.20. 3-(2-(6-(4-Methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydraz-ineylidene)-1-methylindolin-2-one (**6t**) {#sec4.1.3.20}

Yield 419 mg (84%) of yellowish-white powder; mp 253--255 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.13 (1H, br s, D~2~O exchangeable, 3-NH), 8.06--7.97 (2H, m, Ar-2′,6′-H), 7.58 (1H, d, *J* = 7.6 Hz, Ar-4″-H), 7.43 (1H, t, *J* = 7.6 Hz, Ar-6″-H), 7.21--7.13 (3H, m, Ar-3′,5′,7″-H), 7.08 (1H, t, *J* = 7.6 Hz, Ar-5″-H), 4.43 (2H, s, 7-CH~2~), 3.87 (3H, s, 4′-OCH~3~), 3.26 (3H, s, 1″-N-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 162.89 (1C, 2″-*C*=O), 161.98 (1C, 6-*C*), 155.09 (1C, 8a-*C*), 152.90 (1C, 3-*C*), 143.17 (1C, 7″a-*C*), 136.95 (1C, Ar-4′-*C*), 133.53 (1C, 3″-*C*), 130.90 (1C, 6″-*C*H), 129.67 (2C, Ar-2′,6′-*C*H), 125.61 (1C, Ar-1′-*C*), 123.49 (1C, 3″a-*C*), 120.14 (1C, 4″-*C*H), 118.72 (1C, 5″-*C*H), 115.08 (2C, Ar-3,5′-*C*H), 110.28 (1C, 7″-*C*H), 56.07 (1C, 4′-O*C*H~3~), 26.20 (1C, 1″-N-CH~3~), 23.58 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 131.37 (1C, 6″-*C*H), 129.66 (2C, Ar-2′,6′-*C*H), 120.82 (1C, 4″-*C*H), 115.02 (2C, Ar-3,5′-*C*H), 111.29 (1C, 7″-*C*H), 56.04 (1C, 4′-O*C*H~3~), 23.53 (1C, 7-*C*H~2~), 21.08 (1C, 5″-*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~20~H~18~N~7~O~2~S \[M + H\]^+^, 420.1243; found, 420.1242.

#### 4.1.3.21. 5-Chloro-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)-1-methylindolin-2-one (**6u**) {#sec4.1.3.21}

Yield 417 mg (92%) of yellowish-white powder; mp 277--279 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.10 (1H, br s, D~2~O exchangeable, 3-NH), 8.74 (1H, s, Ar-4″-H), 8.10 (2H, d, *J* = 8.6 Hz, Ar-2′,6′-H), 7.34 (1H, d, *J* = 8.3 Hz, Ar-7″-H), 7.10 (2H, d, *J* = 8.6 Hz, Ar-3′,5′-H), 7.02 (1H, d, *J* = 8.3 Hz, Ar-6″-H), 4.45 (2H, s, 7-CH~2~), 3.87 (3H, s, 4′-OCH~3~), 3.19 (3H, s, 1″-N-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 164.80 (1C, 2″-*C*=O), 162.73 (1C, 6-*C*), 155.08 (1C, 8a-*C*), 154.70 (1C, 3-*C*), 141.50 (1C, 7″a-*C*), 139.28 (1C, Ar-4′-*C*), 138.64 (1C, 3″-*C*), 129.68 (1C, 5″-*C*), 129.54 (2C, Ar-2′,6′-*C*H), 128.67 (1C, 6″-*C*H), 126.14 (1C, Ar-1′-*C*), 126.00 (1C, 3″a-*C*), 123.90 (1C, 4″-*C*H), 114.88 (2C, Ar-3,5′-*C*H), 109.73 (1C, 7″-*C*H), 56.04 (1C, 4′-O*C*H~3~), 26.27 (1C, 1″-N-CH~3~), 22.61 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.54 (2C, Ar-2′,6′-*C*H), 128.67 (1C, 6″-*C*H), 123.86 (1C, 4″-*C*H), 114.88 (2C, Ar-3,5′-*C*H), 109.74 (1C, 7″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 26.27 (1C, 1″-N-CH~3~), 22.61 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~20~H~17~ClN~7~O~2~S \[M + H\]^+^, 454.0853; found, 454.0854.

#### 4.1.3.22. 5-Bromo-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydra-zineeylidene)-1-methylindolin-2-one (**6v**) {#sec4.1.3.22}

Yield 418 mg (84%) of yellowish-white powder; mp 290--292 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.08 (1H, br s, D~2~O exchangeable, 3-NH), 8.90 (1H, s, Ar-4″-H), 8.11 (2H, d, *J* = 8.6 Hz, Ar-2′,6′-H), 7.47 (1H, d, *J* = 8.2 Hz, Ar-7″-H), 7.12 (2H, d, *J* = 8.6 Hz, Ar-3′,5′-H), 6.98 (1H, d, *J* = 8.3 Hz, Ar-6″-H), 4.45 (2H, s, 7-CH~2~), 3.87 (3H, s, 4′-OCH~3~), 3.19 (3H, s, 1″-N-CH~3~). ^13^C NMR (125 MHz, DMSO): δ 164.67 (1C, 2″-*C*=O), 162.76 (1C, 6-*C*), 154.88 (1C, 8a-*C*), 154.73 (1C, 3-*C*), 141.85 (1C, 7″a-*C*), 139.28 (1C, Ar-4′-*C*), 138.45 (1C, 3″-*C*), 131.47 (1C, 6″-*C*H), 129.57 (2C, Ar-2′,6′-*C*H), 129.04 (1C, 5″-*C*), 125.94 (1C, Ar-1′-*C*), 123.90 (1C, 4″-*C*H), 119.73 (1C, 3″a-*C*), 114.96 (2C, Ar-3,5′-*C*H), 110.27 (1C, 7″-*C*H), 56.06 (1C, 4′-O*C*H~3~), 26.25 (1C, 1″-N-CH~3~), 22.58 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 131.47 (1C, 6″-*C*H), 129.58 (2C, Ar-2′,6′-*C*H), 123.91 (1C, 4″-*C*H), 114.97 (2C, Ar-3,5′-*C*H), 110.29 (1C, 7″-*C*H), 56.06 (1C, 4′-O*C*H~3~), 26.24 (1C, 1″-N-CH~3~), 22.57 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~20~H~17~BrN~7~O~2~S \[M + H\]^+^, 498.0348; found, 498.0352.

#### 4.1.3.23. 5-Chloro-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineylidene)-1-propylindolin-2-one (**6w**) {#sec4.1.3.23}

Yield 448 mg (93%) of yellowish-white powder; mp 266--268 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.06 (1H, br s, D~2~O exchangeable, 3-NH), 8.75 (1H, s, Ar-4″-H), 8.09 (2H, d, *J* = 8.5 Hz, Ar-2′,6′-H), 7.31 (1H, d, *J* = 8.1 Hz, Ar-7″-H), 7.18--6.98 (3H, m, Ar-3′,5′-H and Ar-6″-H), 4.45 (2H, s, 7-CH~2~), 3.86 (3H, s, 4′-OCH~3~), 3.69 (2H, t, *J* = 7.0 Hz, 1″-N-C*H*~2~CH~2~CH~3~), 1.61 (2H, m, 1″-N-CH~2~C*H*~2~CH~3~), 0.88 (3H, t, *J* = 8.3 Hz, 1″-N-CH~2~CH~2~C*H*~3~). ^13^C NMR (125 MHz, DMSO): δ 164.80 (1C, 2″-*C*=O), 162.72 (1C, 6-*C*), 154.92 (1C, 8a-*C*), 154.67 (1C, 3-*C*), 141.83 (1C, 7″a-*C*), 139.29 (1C, Ar-4′-*C*), 138.77 (1C, 3″-*C*), 129.69 (1C, 5″-*C*), 129.54 (2C, Ar-2′,6′-*C*H), 128.61 (1C, 6″-*C*H), 126.36 (1C, 4″-*C*H), 126.00 (2C, Ar-1′-*C* and 3″a-*C*), 114.87 (2C, Ar-3,5′-*C*H), 109.91 (1C, 7″-*C*H), 56.04 (1C, 4′-O*C*H~3~), 23.63 (1C, 1″-N-*C*H~2~CH~2~CH~3~), 22.60 (1C, 7-*C*H~2~), 21.12 (1C, 1″-N-CH~2~*C*H~2~CH~3~), 11.63 (1C, 1″-N-CH~2~CH~2~*C*H~3~). DEPT C^135^ (125 MHz, DMSO): δ 129.54 (2C, Ar-2′,6′-*C*H), 128.63 (1C, 6″-*C*H), 126.36 (1C, 4″-*C*H), 114.87 (2C, Ar-3,5′-*C*H), 109.92 (1C, 7″-*C*H), 56.03 (1C, 4′-O*C*H~3~), 23.63 (1C, 1″-N-*C*H~2~CH~2~CH~3~), 22.59 (1C, 7-*C*H~2~), 21.13 (1C, 1″-N-CH~2~*C*H~2~CH~3~), 11.63 (1C, 1″-N-CH~2~CH~2~*C*H~3~). HRMS (ES+): *m*/*z* calcd for C~22~H~21~ClN~7~O~2~S \[M + H\]^+^, 482.1166; found, 482.1170.

#### 4.1.3.24. 1-Benzyl-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazineyl idene)indolin-2-one (**6x**) {#sec4.1.3.24}

Yield 406 mg (82%) of yellowish-white powder; mp 242--244 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.12 (1H, br s, D~2~O exchangeable, 3-NH), 8.01 (2H, d, *J* = 8.5 Hz,, Ar-2′,6′-H), 7.61 (1H, d, *J* = 7.4 Hz, Ar-4″-H), 7.42--7.21 (6H, m, Ar-3′,5′,5″, 6″, 2‴,6‴-H), 7.20--7.09 (3H, m, Ar-3‴,4‴,5‴-H), 7.04 (1H, d, *J* = 7.5 Hz, Ar-7″-H), 5.05 (2H, s, 1″-N-CH~2~Ph), 4.44 (2H, s, 7-CH~2~), 3.85 (3H, s, 4′-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 162.87 (1C, 2″-*C*=O), 162.02 (1C, 6-*C*), 155.16 (1C, 8a-*C*), 154.74 (1C, 3-*C*), 141.96 (1C, 7″a-*C*), 138.59 (1C, Ar-4′-*C*), 133.16 (1C, 3″-*C*), 130.76 (1C, 6″-*C*H), 129.69 (2C, Ar-2′,6′-*C*H), 129.21 (2C, Ar-2‴,6‴-*C*H), 128.04 (1C, 4″-*C*H), 127.70 (2C, Ar-3‴,5‴-*C*H), 136.21 (1C, Ar-1‴-*C*), 124.38 (2C, Ar-1′-*C* and 3″a-*C*), 123.63 (1C, Ar-4‴-*C*H), 120.31 (1C, 5″-*C*H), 115.08 (2C, Ar-3,5′-*C*H), 110.82 (1C, 7″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 42.91 (2H, s, 1″-N-CH~2~Ph), 23.66 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 130.77 (1C, 6″-*C*H), 129.68 (2C, Ar-2′,6′-*C*H), 129.21 (2C, Ar-2‴,6‴-*C*H), 128.04 (1C, 4″-*C*H), 127.70 (2C, Ar-3‴, 5‴-*C*H), 123.63 (1C, Ar-4‴-*C*H), 120.32 (1C, 5″-*C*H), 115.08 (2C, Ar-3,5′-*C*H), 110.82 (1C, 7″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 42.91 (2H, s, 1″-N-CH~2~Ph), 23.66 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~26~H~22~N~7~O~2~S \[M + H\]^+^, 496.1556; found, 496.1563.

#### 4.1.3.25. 1-Benzyl-5-chloro-3-(2-(6-(4-methoxyphenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thia-diazin-3-yl)hydrazineylidene)indolin-2-one (**6y**) {#sec4.1.3.25}

Yield 477 mg (90%) of yellowish-white powder; mp 285--286 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 13.10 (1H, br s, D~2~O exchangeable, 3-NH), 8.77 (1H, s, Ar-4″-H), 8.10 (2H, d, *J* = 8.5 Hz, Ar-2′,6′-H), 7.39--7.30 (4H, m, Ar-6″, 3‴,4‴,5‴-H), 7.26 (2H, d, *J* = 8.0 Hz,Ar-2‴,6‴-H), 7.10 (2H, d, *J* = 8.5 Hz, Ar-3′,5′-H), 6.93 (1H, d, *J* = 8.4 Hz, Ar-7″-H), 4.98 (2H, s, 1″-N-CH~2~Ph), 4.46 (2H, s, 7-CH~2~), 3.86 (3H, s, 4′-OCH~3~). ^13^C NMR (125 MHz, DMSO): δ 164.93 (1C, 2″-*C*=O), 162.77 (1C, 6-*C*), 154.92 (1C, 8a-*C*), 154.85 (1C, 3-*C*), 140.37 (1C, 7″a-*C*), 139.43 (1C, Ar-4′-*C*), 138.16 (1C, 3″-*C*), 137.23 (1C, Ar-1‴-*C*), 129.57 (2C, Ar-2′,6′-*C*H), 129.13 (2C, Ar-2‴,6‴-*C*H), 128.55 (1C, 4″-*C*H), 127.81 (1C, Ar-4‴-*C*H), 127.60 (2C, Ar-3‴,5‴-*C*H), 126.35 (2C, 6″-*C*H and 5″-*C*), 125.99 (1C, Ar-1′-*C*), 119.55 (1C, Ar-3″a-*C*), 114.91 (2C, Ar-3′,5′-*C*H), 110.30 (1C, 7″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 42.89 (2H, s, 1″-N-CH~2~Ph), 22.62 (1C, 7-*C*H~2~). DEPT C^135^ (125 MHz, DMSO): δ 129.57 (2C, Ar-2′,6′-*C*H), 129.13 (2C, Ar-2‴,6‴-*C*H), 128.55 (1C, 4″-*C*H), 127.60 (2C, Ar-3‴,5‴-*C*H), 127.81 (1C, Ar-4‴-*C*H), 126.36 (1C, 6″-*C*H), 114.91 (2C, Ar-3,5′-*C*H), 110.31 (1C, 7″-*C*H), 56.05 (1C, 4′-O*C*H~3~), 42.89 (2H, s, 1″-N-CH~2~Ph), 22.62 (1C, 7-*C*H~2~). HRMS (ES+): *m*/*z* calcd for C~26~H~21~ClN~7~O~2~S \[M + H\]^+^, 530.1166; found, 530.1170.

4.2. Biological Screening {#sec4.2}
-------------------------

### 4.2.1. In Vitro Cytotoxic Assay (NCI Cell One-Dose Screening Assay)^[@ref57]^ {#sec4.2.1}

Eight compounds were submitted to the NCI Cell screen and tested at a single high dose (10^--5^ M) in the full NCI 58 cell panel including nine subpanels (hematopoietic system, lung cancer, colon, brain, skin melanoma, kidney, ovary, prostate, and breast cancers), as described in detail.^[@ref57]^ Briefly, the human tumor cells were grown with 5% fetal bovine serum and 2 mM [l]{.smallcaps}-glutamine in the medium RPMI 1640. The cancer cells (100 μL) were inoculated in 96-well plates at densities from 5000 to 40,000 cells/well, and the microtiter plates were then incubated at 37 °C, 5% CO~2~, 95% air, and 100% relative humidity for 24 h. Within 24 h, two plates of each cell line were fixed in situ with trichloroacetic acid (TCA) to measure of the population of the cells at the time of addition of each drug (Tz). Compounds **6a**, **6b**, **6e**, **6l**, **6n**, **6r**, **6v**, and **6y** have been diluted in DMSO at 400 times the final concentration (10 μM) and frozen prior to use. During the addition of the test compound, an aliquot of frozen concentrate is thawed and diluted with a medium containing 50 μg/mL gentamicin to double the final concentration. Aliquots of 100 μL of different drug dilutions have been added to 100 μL of the medium in each well, resulting in the required final compound concentrations of 10^--5^ M. The plates were then incubated for an additional 48 h at 37 °C. The experiment was terminated by introducing cold TCA. Cold 50% TCA (50 μL) was gently added and incubated at 4 °C for 1.0 h. The plates were washed five times with H~2~O after discarding the supernatant and dried by air. To each well, 100 μL of 0.4% (w/v) sulforhodamine B in 1% acetic acid was added, and the plates were incubated for 10 min at ambient temperature. Following removing the unbound dye by washing 5× 1% acetic acid, the bound stain was solubilized with 10 mM trizma base, and the absorbance was read using a plate reader at L515 nm. The same protocol was applied with the suspension cells, except for terminating the experiment by adding 50 μL of 80% TCA to fix the settled cells at the bottom of the wells. % growth inhibition was calculated as

The one-dose data were used as a mean graph of the percent growth inhibition of treated cells relative to a negative control. This enables the detection of both the growth inhibition (between 0 and 100) and lethality (less than 0). In this assay, we calculated the growth inhibition by subtracting the % growth from 100, for example, a value of 100 growth means growth inhibition = 0, and a value of 40% growth percentage means 60% growth inhibition.

### 4.2.2. HET-CAM Angiogenesis Study^[@ref49]^ {#sec4.2.2}

#### 4.2.2.1. Choosing an Optimum Nonembryotoxic Concentration of Each Compound {#sec4.2.2.1}

Fertilized hen eggs were incubated at 37 °C for 5 days with rotation for every 2 h. The viability of the incubated eggs was examined, and the air sac for every viable egg was determined by candling at the beginning of the 5th day. The dead ones were excluded from the test. An observatory window was opened at the contralateral location and covered with a sterilized adhesive tape. Eggs were returned to the incubator. On the 9th day, the adhesive tape was removed. The fewer blood vessel density area on CAM was determined, and then, 40 μL of the various concentrations of each compound dissolved in DMSO 40 or 100% in saline was added dropwise on a sterilized filter paper disc of 5 mm with an inner hole of 2.5 mm in diameter (3 eggs/concentration), and the exposed window was covered again by a sterile adhesive tape. The toxicity of each compound on the eggs was examined on the 11th day by candling (Galal et al., 2016).^[@ref49]^

#### 4.2.2.2. Testing the Effect of Synthesized compounds on HET-CAM Angiogenesis {#sec4.2.2.2}

The experiment was carried out as follows: the optimum nontoxic concentration of each compound (40 or 100 μM) was added on the filter paper disc. Fertilized eggs were incubated for 9 days at the same conditions and divided into the groups of three eggs. Each compound (40 μM) dissolved in 40 μL of 40% DMSO in saline was added dropwise on the filter paper disc. A control group was used where 40 μL of 40% DMSO in saline was used.

#### 4.2.2.3. Quantitative Assessment of Angiogenesis on HET-CAM Using Image Analysis {#sec4.2.2.3}

The effect of the test materials on CAM angiogenesis was examined on the 11th day. An angiography was taken for every sampled egg. The examination was carried out using computerized image analysis to count newly formed small blood vessels in the circle of 100 mm^2^ area representing a standard area for all the angiographs where the blood vessels were analyzed (Galal et al., 2016).^[@ref49]^ The procedures were carried out for each test group, and the data were collected, tabulated, and statistically analyzed using a one-way ANOVA test, followed by Dunnett's multiple comparison test.

### 4.2.3. VEGFR-2, PDGFR, and C-Met Kinase Inhibitory Assays {#sec4.2.3}

The design and protocol for these assays for the selected compounds **6b** were designed according to the reported procedures.^[@ref18],[@ref19][@ref58]^

4.3. Molecular Modeling Study {#sec4.3}
-----------------------------

Molecular docking study was conducted using Accelrys software (Discovery Studio 4) for compound **6b** against VEGFR-2 (PDB code: 4AGD) and c-MET kinase (PDB code: 3ZZE). The 3D protein structures were retrieved from PDB^[@ref60]^ and then prepared for docking by adding missing loops, removing water molecules, and adding the missing hydrogens. The cocrystallized ligand and compound **6b** were drawn and prepared by preparing ligand protocol to generate a 3D structure and refined using the CHARMM force field with full potential. Docking simulations were run using CDOCKER, and the top 10 docking poses would be finally saved. The docking process was verified by the alignment of the cocrystallized ligand and docked ligand to calculate rmsd values which were 0.95 and 0.87 Å, respectively. The docked poses were ranked according to their CDOCKER interaction energy, and the top pose was chosen for the analysis of interactions for each compound.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c02038](https://pubs.acs.org/doi/10.1021/acsomega.0c02038?goto=supporting-info).^1^H NMR, ^13^C DEPT, ^13^C NMR, and HRMS spectra of compounds **5a--6y** and DTP-NCI 60 cell mean graphs for eight compounds (**6a**, **6b**, **6e**, **6l**, **6n**, **6r**, **6v**, and **6y**) ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02038/suppl_file/ao0c02038_si_001.pdf))
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